Proceeds from the Offer will be used for:
• Working capital ‒ General working capital that is sufficient for ImpediMed to achieve breakeven, including advance inventory purchases to address growth, current global chip shortages, COVID-19 related supply chain issues and transition to SOZO II
• Product enhancements ‒ SOZO II development, including weight scales and improved electronics for Renal Failure and Heart Failure
• Data and software enhancements ‒ Corporate account development including electronic health record integration and heart failure programs
• Development and commercialisation of renal failure application ‒ End stage renal disease clinical trial and US FDA clearance
I'm happy with this ... glad there were no options!
Ann: Capital Raising Presentation, page-2
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $153.7M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.4¢ | $140.4K | 1.863M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 149896 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 136785 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.000 ( 2.56 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.8¢ | 7.4¢ | 410811 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| IPD (ASX) Chart |